HALO

Based on Halozyme Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Halozyme Therapeutics do?

Halozyme is a biopharma technology platform company. Its core business is licensing the ENHANZE drug delivery technology — based on a patented enzyme — to pharmaceutical partners who use it to reformulate injectable biologics for subcutaneous delivery. Revenue comes primarily from royalties and licensing fees rather than direct drug sales.

Does HALO pay dividends?

Halozyme does not pay a dividend. The company reinvests capital into growing its ENHANZE partnership network and supporting research collaborations. Investors in HALO are typically focused on long-term platform growth rather than dividend income.

When does HALO report earnings?

Halozyme reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact upcoming reporting dates, check Halozyme's investor relations page directly, as our data source does not cover specific future earnings dates.

Is HALO a good stock to buy?

UQS Score rates HALO as Excellent, one of the highest ratings on the platform. Strong Quality, Growth, and Risk pillar scores alongside an Attractive Valuation rating reflect a well-structured business. Whether it fits your portfolio depends on your individual goals — the full pillar breakdown is available to Pro members.

Is HALO overvalued?

The UQS Valuation pillar for HALO is rated Attractive, suggesting the stock may be reasonably priced relative to its fundamental quality profile. This does not constitute a price prediction, but it indicates the market may not be fully reflecting the platform's long-term earnings potential.

How does HALO compare to its competitors?

Halozyme's platform-licensing model sets it apart from most biopharma peers. Unlike clinical-stage developers such as Cytokinetics or ImmunityBio, Halozyme generates royalty revenue from already-commercialized partner products, which creates a more predictable revenue base. The UQS competitor comparison tool lets Pro members view side-by-side pillar scores.

What is HALO's market cap bracket?

Halozyme Therapeutics is classified as a mid-cap company. This places it in a range that often combines meaningful revenue scale with continued growth potential, though mid-cap stocks can carry more volatility than large- or mega-cap peers.

Who founded Halozyme Therapeutics?

Halozyme Therapeutics was founded in 2004 and is headquartered in San Diego, California. For detailed founding history and leadership background, the company's official about page and public filings are the most reliable sources.

Is HALO a long-term quality stock?

The UQS Score evaluates long-term fundamental quality across five pillars. HALO's Excellent overall rating, supported by Strong scores in Quality, Growth, and Risk, suggests a business with durable characteristics. Long-term suitability still depends on individual risk tolerance and portfolio context — the full analysis is available to Pro members.

What is the main competitive advantage of Halozyme?

Halozyme's primary advantage is the ENHANZE platform — a patented enzyme-based technology that allows injectable biologics to be delivered subcutaneously. This creates a licensing moat: partners pay royalties on approved products for years, generating recurring revenue without Halozyme bearing the full cost of drug development.

Is HALO a growth stock or value stock?

Based on UQS pillar labels, HALO exhibits characteristics of both. The Growth pillar is rated Strong, reflecting expanding royalty streams and a growing partner base. The Valuation pillar is rated Attractive, which is uncommon for high-growth healthcare names — making HALO an interesting case for investors seeking quality at a reasonable price.

Halozyme Therapeutics, Inc. demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.

Halozyme Therapeutics, Inc. is growing rapidly with strong revenue and earnings expansion.

Halozyme Therapeutics, Inc. has some risk factors including moderate leverage or solvency concerns.

Halozyme Therapeutics, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.

Halozyme Therapeutics, Inc. has meaningful competitive advantages that should protect its market position. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for HALO.

The UQS (Unified Quality Score) for Halozyme Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Halozyme Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Halozyme Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.